CSIMarket
 
Kala Bio inc   (KALA)
Other Ticker:  
 
 
Price: $7.5300 $-0.10 -1.311%
Day's High: $7.7897 Week Perf: -3.71 %
Day's Low: $ 7.51 30 Day Perf: 9.61 %
Volume (M): 12 52 Wk High: $ 19.57
Volume (M$): $ 89 52 Wk Avg: $11.06
Open: $7.51 52 Wk Low: $5.10



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Kala Bio Inc
Kala Bio Inc. is a biopharmaceutical company that specializes in the development of innovative therapies for various eye conditions. The company utilizes a proprietary technology platform called AMPPLIFY to enhance the bioavailability and efficacy of its products. Kala Bio's primary focus is on developing treatments for diseases such as dry eye disease, macular edema, and retinal diseases. Their goal is to improve the lives of patients by providing effective and convenient treatment options for these conditions.


   Company Address: 1167 Massachusetts Avenue Arlington 2476 MA
   Company Phone Number: 996-5252   Stock Exchange / Ticker: NASDAQ KALA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

KALA BIO Enriches Workforce with Inducement Grants Amidst Market Challenges, Prioritizing Long-Term Growth Vision

Published Fri, Jan 19 2024 9:01 PM UTC



ARLINGTON, Mass., Jan. 19, 2024 - KALA BIO, Inc. (Nasdaq:KALA), a leading pharmaceutical company specializing in innovative treatments, issued a press release today disclosing the granting of non-statutory stock options to a new employee as an inducement award. This award falls outside the purview of the Company's Amended and Restated 2017 Equity Incentive Plan, in...

Kala Bio Inc

Revitalizing Achievements by Kala Bio Inc. Exceed Expectations During the Third Quarter of 2023 Earnings Season

Kala Bio Inc, a biopharmaceutical company, recently reported its third-quarter earnings for the 2023 season. The company's earnings per share (EPS) saw a significant decrease, with a loss of $-3.41 per share compared to $19.25 per share from a year ago. However, there was an improvement in EPS from the preceding quarter, which was $-4.36 per share.
The revenue for the third quarter remained unchanged at $0.00 million, compared to $0.42 million in the corresponding quarter last year and sequentially from $0.00 million. This indicates that the company's revenue has seen a decline over the past year. Additionally, Kala Bio Inc recorded a net deficit of $-8.704 million for the third quarter, rather than the net proceeds of $29.073 million achieved in the same quarter the previous year.

Kala Bio Inc

Despite Stagnation in Major Pharmaceutical Sector, Kala Bio Inc Reports Increasing Deficit in Q2 of 2023 Financial Results



Kala Bio Inc, a pharmaceutical company, recently released its financial results for the second quarter of 2023 earnings season. This article aims to interpret and outline the facts from these results, providing a comprehensive understanding of the company's performance during this period.
Financial Results:
1. Deficit Expansion: Kala Bio Inc's deficit per share expanded significantly from $-0.38 in the same quarter a year earlier to $-4.36 in the second quarter of 2023. This negative trend indicates a decline in profitability.

Kala Pharmaceuticals Inc

Kala Pharmaceuticals Inc Makes Remarkable Strides Amidst a Challenging Fiscal Year

Kala Pharmaceuticals Inc is a biopharmaceutical company that develops and markets innovative medicines to combat eye diseases and inflammation. Founded in 2009 and headquartered in Massachusetts, USA, the company has been striving to bring transformative treatments to patients in need. Despite facing significant challenges in the past years, Kala Pharmaceuticals Inc has been making notable progress toward its goals.
The latest financial report from Kala Pharmaceuticals Inc for the fiscal year ending March 31 2023 shows mixed results. While the company has been successful in reducing its net loss and improving its EPS from the previous financial period, the losses per share have increased significantly. This sudden rise in losses per share can be attributed to the company's investments in research and development, expanding its product portfolio, and regulatory compliance. These factors contribute to higher operating costs, which have weighed heavily on the company's bottom line.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com